Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion

HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially single-shot alternative, B cells engineered by CRISPR/Cas9 to express anti-HIV broadly neutralizing antibodies (bNAbs) are capable of secreting high antibody titers. Here, we show that, upon immunization of mice, adopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Nahmad, Alessio D., Raviv, Yuval, Horovitz-Fried, Miriam, Sofer, Ilan, Akriv, Tal, Nataf, Daniel, Dotan, Iris, Carmi, Yaron, Burstein, David, Wine, Yariv, Benhar, Itai, Barzel, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673991/
https://www.ncbi.nlm.nih.gov/pubmed/33203857
http://dx.doi.org/10.1038/s41467-020-19649-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673991/
https://www.ncbi.nlm.nih.gov/pubmed/33203857
http://dx.doi.org/10.1038/s41467-020-19649-1

Ejemplares similares